Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Swedish Orphan Biovitrum AB ( (SE:SOBI) ) is now available.
Swedish Orphan Biovitrum AB (Sobi) announced the FDA approval of Gamifant (emapalumab-lzsg) as the first treatment for adults and children with Macrophage Activation Syndrome (MAS) in Still’s disease. This approval, based on pivotal studies showing significant patient response, positions Gamifant as a critical therapeutic option, addressing unmet medical needs and potentially improving patient outcomes in this severe condition.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Sobi is a global biopharmaceutical company focused on transforming the lives of people with rare diseases through innovative treatments. With approximately 1,900 employees worldwide, Sobi operates across Europe, North America, the Middle East, Asia, and Australia, and reported a revenue of SEK 26 billion in 2024. The company is listed on Nasdaq Stockholm under the ticker STO:SOBI.
Average Trading Volume: 357,997
Current Market Cap: SEK95.21B
Find detailed analytics on SOBI stock on TipRanks’ Stock Analysis page.